GLG Pharma is an oncology company-- and they’re ready to improve cancer treatments. The current treatment for ovarian cancer only leads to about a 40% survival rate. However, GLG Pharma believes that by inhibiting STAT3, a mechanism found in over 30 types of cancer, they can help people respond more successfully to treatment by 10-20%. In fact, their goal is that, in the next five years with their research, they think they could raise the survival rate to 60-70%. So far, GLG was selected by the National Cancer Institute’s PREVENT Cancer Preclinical Drug Development Program for breast cancer, and they received a $3.7M grant from an EU supported fund in Poland for Triple Negative Breast Cancer treatment. Plus, the founder has already had nine drugs be approved by the FDA & EMA.